GSK CEO Andrew Witty dedicates albendazole facility in Nashik to WHO’s Global Programme to Eliminate LF
London UK - GlaxoSmithKline (GSK) CEO Andrew Witty today dedicated a new production facility at its Nashik site in India to the manufacture of albendazole, part of a combination treatment used within the World Health Organization’s (WHO) Global Programme to Eliminate Lymphatic Filariasis (LF).
This facility reaffirms the healthcare company’s commitment to global public health with a focus on diseases of the developing world. This new facility, built with an investment of Rs.15 million (US$ 330,000), will deliver an additional 300 million treatments of albendazole per year, which is the largest drug donation programme in the history of the global pharmaceutical industry.
The global programme to eliminate LF has become the most rapidly scaled up drug administration programme in public health history. Since the programme began in 2000, more than 1.9 billion treatments have been given to over 570 million people in 48 of the 83 countries with endemic LF.
Andrew Witty, GlaxoSmithKline’s CEO said: “Thirty years ago, scientific breakthroughs led to the eradication of smallpox. Today we have hope that another disease, Lymphatic Filariasis, can be consigned to the history books. Promising new data show that the simplicity of the WHO’s disease elimination programme is working. Through this investment in India we are able to focus on one of the largest areas at risk from LF and support the Indian Government’s current efforts to control and eliminate this crippling tropical disease.”
He added, “It is truly humbling to be a part of a programme that has managed to treat 570 million people in 48 countries. GSK is proud of the role we have played in the LF programme and we are fully committed to ridding the world of this disease.”
Worldwide more than 1.3 billion people live at risk of disability and disfigurement caused by LF, one-third of those at risk live in India. The cost to the Indian economy is estimated to exceed US$840m every year due to treatment costs, reduced working time and lost productivity.
The Nashik facility will potentially save the Indian health system an estimated Rs. 1.38 billion (US$ 30 million) in treatment costs and improve lives of 550 million people in India who live at risk of developing this debilitating condition.
The Nashik facility accounts for half of GSK’s annual manufacturing capacity for the LF programme. The technology for this plant was transferred from Cape Town and production started in August 2009. The first consignment of 15 million albendazole tablets was supplied to WHO on 23rd December, 2009. This year Nashik is expected to deliver 300 million tablets.
Since its initiation, the international effort to eliminate LF has made unprecedented strides towards ridding the world of one of its most debilitating diseases. The cost-efficiency combined with the programme’s achievements have made the LF elimination effort a model for future large-scale international public health partnerships and has prompted officials to call for the development of a dedicated fund for the treatment and elimination of other neglected tropical diseases.
As the Global Programme continues towards its goal of eliminating LF by 2020, the coming years will see additional rapid growth and expansion.
About lymphatic filariasis – Lymphatic filariasis, often called elephantiasis, is a parasitic infection spread by mosquitoes that causes grotesque, painful swelling of the limbs, breasts, and genitals. Considered a neglected tropical disease, LF almost exclusively affects the world’s poorest people. Approximately one fifth of the world’s population (1.3 billion people) is at risk of contracting LF and approximately 120 million people in 83 countries are currently infected.
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.